These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17869375)

  • 1. Interferon-based therapy of hepatitis C.
    Chevaliez S; Pawlotsky JM
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1222-41. PubMed ID: 17869375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel interferons for treatment of hepatitis C virus.
    Clark V; Nelson DR
    Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future therapies for hepatitis C.
    Pawlotsky JM; Gish RG
    Antivir Ther; 2006; 11(4):397-408. PubMed ID: 16856613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
    Feld JJ; Hoofnagle JH
    Nature; 2005 Aug; 436(7053):967-72. PubMed ID: 16107837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy for hepatitis C.
    TreatmentUpdate; 1998 Mar; 10(1):2-3. PubMed ID: 11365430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribavirin approved with a big fat price.
    Falkenberg J
    Notes Undergr; 1998; (No 37):10-1. PubMed ID: 11365818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutic strategies for hepatitis C.
    Di Bisceglie AM; McHutchison J; Rice CM
    Hepatology; 2002 Jan; 35(1):224-31. PubMed ID: 11786980
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience.
    Tanioka D; Iwasaki Y; Araki Y; Osawa T; Ikeda H; Ando M; Kobashi H; Sakaguchi K; Shiratori Y; Yamamoto K
    Liver Int; 2009 May; 29(5):721-9. PubMed ID: 19141025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral therapy: chronic hepatitis C.
    Heathcote EJ
    J Viral Hepat; 2007 Nov; 14 Suppl 1():82-8. PubMed ID: 17958648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
    Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
    J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of combined antiviral therapy with interferon alfa and ribavirin in chronic hepatitis C patients with extrahepatic manifestations].
    Zarebska-Michaluk D; Lebensztejn DM; Kryczka W
    Przegl Epidemiol; 2007; 61(3):551-8. PubMed ID: 18069393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells.
    Colombatto P; Ciccorossi P; Maina AM; Civitano L; Oliveri F; Coco B; Romagnoli V; Bonino F; Brunetto MR
    Clin Pharmacol Ther; 2008 Aug; 84(2):212-5. PubMed ID: 18388885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders.
    Freedman K; Nathanson J
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):363-76. PubMed ID: 19344248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for hepatitis C therapeutic intervention: now and next.
    Tan SL; He Y; Huang Y; Gale M
    Curr Opin Pharmacol; 2004 Oct; 4(5):465-70. PubMed ID: 15351350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interferon therapy in chronic active viral hepatitis].
    Lengyel G; Fehér J
    Orv Hetil; 1995 Jan; 136(1):3-7. PubMed ID: 7531317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C and the 'cure'.
    Cooksley WG
    Aust Fam Physician; 1998 Dec; 27(12):1086. PubMed ID: 9919728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.